The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Crizotinib Continuation Clinical Study
Official Title: CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES
Study ID: NCT05160922
Brief Summary: The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.
Detailed Description: Participants not previously enrolled or who have discontinued study treatment or safety follow-up in a current Pfizer sponsored crizotinib clinical study are not eligible for participation in this continuation study.
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
Beijing Cancer Hospital, Beijing, Beijing, China
Fujian Province Oncology Hospital, Fuzhou, Fujian, China
Sun Yat-Sen University Cancer center, Guangzhou, Guandong, China
The First Affiliated Hospital of Guangzhou Medical University., Guang Zhou, Guangdong, China
Sun Yat-Sen University Cancer center, Guangzhou, Guangdong, China
Sun Yat-Sen University Cancer center, Guangzhou, Guangdong, China
Jilin Cancer Hospital, Changchun, Jilin, China
West China Hospital of Sichuan University, Wuhou District,Chengdu, Sichuan, China
The First Affiliated Hospital of College of Medicine,Zhejiang University, Hangzhou, Zhejiang, China
The First Affiliated Hospital of Guangzhou Medical University., Guangzhou, , China
Shanghai Chest Hospital, Shanghai, , China
ASST Monza, Monza, MB, Italy
National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan
Limited Liability Company "EuroCityClinic", Saint-Petersburg, , Russian Federation
National Taiwan University Hospital, Taipei, , Taiwan
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR